In vitro and in vivo analysis of B-Myb in basal-like breast cancer - PubMed (original) (raw)

In vitro and in vivo analysis of B-Myb in basal-like breast cancer

A R Thorner et al. Oncogene. 2009.

Abstract

A defining feature of basal-like breast cancer, a breast cancer subtype with poor clinical prognosis, is the high expression of 'proliferation signature' genes. We identified B-Myb, a MYB family transcription factor that is often amplified and overexpressed in many tumor types, as being highly expressed in the proliferation signature. However, the roles of B-Myb in disease progression, and its mammary-specific transcriptional targets, are poorly understood. Here, we showed that B-Myb expression is a significant predictor of survival and pathological complete response to neoadjuvant chemotherapy in breast cancer patients. We also identified a significant association between the G/G genotype of a nonsynonymous B-Myb germline variant (rs2070235, S427G) and an increased risk of basal-like breast cancer [OR 2.0, 95% CI (1.1-3.8)]. In immortalized, human mammary epithelial cell lines, but not in basal-like tumor lines, cells ectopically expressing wild-type B-Myb or the S427G variant showed increased sensitivity to two DNA topoisomerase IIalpha inhibitors, but not to other chemotherapeutics. In addition, microarray analyses identified many G2/M genes as being induced in B-Myb overexpressing cells. These results confirm that B-Myb is involved in cell cycle control, and that its dysregulation may contribute to increased sensitivity to a specific class of chemotherapeutic agents. These data provide insight into the influence of B-Myb in human breast cancer, which is of potential clinical importance for determining disease risk and for guiding treatment.

PubMed Disclaimer

Figures

Figure 1

Figure 1. B-Myb expression across breast cancer subtypes

The NKI breast tumor microarray dataset (n=295) was classified into the five intrinsic subtypes and box plots used to visualize B-Myb expression according to breast cancer subtypes. Statistical significance was calculated by ANOVA.

Figure 2

Figure 2. High expression of B-Myb correlates with poor outcome

Kaplan-Meier survival analyses based on B-Myb expression values rank ordered into halves (low/high). (A-D) Overall survival (OS) of locally treated NKI tumor samples: (A) All subtypes combined (n=165), (B) Luminal A (n=72), (C) Luminal B (n=26), (D) HER2+/ER− (n=21). (E) RFS, Wang et al., 2005 (n=286), a locally treated, lymph-node-negative tumor microarray dataset. (F) Miller et al., 2005 breast tumor microarray dataset (n=234).

Figure 3

Figure 3. Drug sensitivities in B-Myb overexpressing cell lines

IC50 doses (72h) of chemotherapy on cell lines stably expressing vector control, B-Myb, or B-Myb S427G variant. Each MTT experiment was performed in triplicate and error bars represent 95% confidence intervals (*p<0.001 relative to vector control). (A) _hTERT_-immortalized HMEC line HME-CC. (B) _hTERT_-immortalized HMEC line ME16C. (C) Basal-like tumor derived cell line SUM102 and (D) SUM149.

Figure 4

Figure 4. Enrichment of G2/M phase genes in doxorubicin-treated B-Myb overexpressing HME-CC cells

Significance Analysis of Microarray was used to identify 217 significant genes whose high expression was present in B-Myb overexpressing cells. These genes were then assigned to a specific phase of the cell cycle by comparing them to Whitfield et al., 2002, which identified 101/217 genes as being specifically induced during the cell cycle. The graph shows to which phase of the cell cycle these 101 genes mapped.

Figure 5

Figure 5. Cell cycle profile of HME-CC cells stably expressing B-Myb and treated with doxorubicin

Cell cultures were treated with a range of doses of doxorubicin for 48 hours followed by propidium iodide DNA content analysis. Percentage of cells in (A) G1 phase and (B) G2/M were calculated by gating based on DNA content. Error bars indicate standard deviations between three independent experiments.

References

    1. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes, Chromosomes and Cancer. 2006;45:1033–1040. - PubMed
    1. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The Triple Negative Paradox : Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res. 2007;13:2329–2334. - PubMed
    1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502. - PubMed
    1. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W-L, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10:529–541. - PubMed
    1. Davidson CJ, Tirouvanziam R, Herzenberg LA, Lipsick JS. Functional Evolution of the Vertebrate Myb Gene Family: B-Myb, but Neither A-Myb nor c-Myb, Complements Drosophila Myb in Hemocytes. Genetics. 2005;169:215–229. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources